Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Observational × Immunomodulating Agents × Clear all

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Neoplasms 1 Heart Diseases 1 Cardiotoxicity 1

Interventions

Surveys and Questionnaires 235 Blood Specimen Collection 124 Gene Expression Profiling 85 Interviews as Topic 70 Immunohistochemistry 64 Polymerase Chain Reaction 55 Surgical Procedures, Operative 49 Microarray Analysis 48 Magnetic Resonance Spectroscopy 47 Radiotherapy 43 Flow Cytometry 43 Amplified Fragment Length Polymorphism Analysis 40 Drug Therapy 38 Observation 36 Biopsy 35 Reverse Transcriptase Polymerase Chain Reaction 33 Data Collection 32 Bevacizumab 31 Therapeutics 23 Psychiatric Rehabilitation 23 Nivolumab 23 In Situ Hybridization, Fluorescence 22 Sorafenib 21 Focus Groups 21 palbociclib 20 Rituximab 20 Neoadjuvant Therapy 20 Magnetic Resonance Imaging 20 Docetaxel 20 Blotting, Western 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03530215 2023-04-13

EROCA

Groupe Hospitalier Pitie-Salpetriere

500,000 enrolled

Heart Diseases, Neoplasms, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡